New MRI dye could sharpen view of heart damage in AF patients
NCT ID NCT07083115
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new MRI contrast agent called Gadopiclenol to see if it provides clearer images of heart damage in people with atrial fibrillation (AF). Researchers will compare it to standard contrast agents in 50 AF patients. The goal is to improve diagnosis and guide treatment for AF.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Gadopiclenol (a new MRI contrast agent)
What this could lead to
If successful, this could lead to clearer MRI images of heart damage in atrial fibrillation patients, helping doctors diagnose and plan treatment more accurately.
What could go wrong
This is a small, early-phase imaging study focused on image quality, not treatment. The new contrast agent may not prove significantly better than current agents, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION (AF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44106, United States